Anti-Mouse TIGIT Polyclonal Antibody (MS739014)

Name: Anti-Mouse TIGIT Polyclonal Antibody
Brand: abinScience
SKU: MS739014
Price: 168 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50ug
100ug

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

MS739014

Reactivité des espèces

Mouse

Applications

ELISA, IHC, WB

Espèce hôte

Rabbit

Clonalité

Polyclonal

Isotype

IgG

Immunogène

E. coli - derived recombinant Mouse TIGIT (Gly28-Glu131).

Cible

T-cell immunoreceptor with Ig and ITIM domains, TIGIT, V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, VSIG9, VSTM3

Niveau d'endotoxines

Please contact with the lab for this information.

Pureté

>90% as determined by SDS-PAGE.

Purification

Purified by antigen affinity column.

Numéro d'accès

P86176

Forme

Liquid

Tampon de stockage

0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a ~26 kDa protein. Inhibitory receptor that plays a role in the modulation of immune responses. Suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. Upon binding to its ligands PVR/CD155 or NECTIN2/CD112, which are expressed on antigen-presenting cells, sends inhibitory signals to the T-cell or NK cell. Mechanistically, interaction with ligand leads to phosphorylation of the cytoplasmic tail by Src family tyrosine kinases such as FYN or LCK, allowing subsequent binding to adapter GRB2 and SHIP1/INPP5D. In turn, inhibits PI3K and MAPK signaling cascades. TIGIT is the therapeutic target of tiragolumab (clinical).

Note

For research use only.

Images

Reférences

Fiche technique